All Antibiotics articles – Page 2
-
ArticleStrategic planning in ADC development: insights from Lonza
Preclinical and clinical development are critical to the success of ADCs, where early strategic decisions regarding manufacturability and scalability can make or break a project. Iwan Bertholjotti of Lonza emphasises the importance of proactive planning to avoid costly delays and ensure smooth progress towards clinical success.
-
ArticleSpirulina’s role in shaping the future of preventative biologics
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we ...
-
NewsScientists turn superbug MRSA into treatable infection
Researchers have discovered a breakthrough method to silence MRSA's drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs.
-
NewsGlox Therapeutics secures £500K to develop antibiotics for cystic fibrosis
Glox Therapeutics has received a portion of a £3 million fund to combat antimicrobial resistance in cystic fibrosis patients.
-
NewsUVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
-
NewsPhage therapy: A step forward in the fight against antibiotic resistance
A new study shows how phages, viruses that kill bacteria, can coexist on a single bacterial strain. This offers valuable insights for developing more effective therapies against antibiotic-resistant infections.
-
NewsE. coli alters ribosomes to survive antibiotic treatment
New study shows E. coli resists antibiotics by modifying its ribosome structure, blocking drug binding and enabling growth despite treatment.
-
NewsP. aeruginosa infection method elucidated with microtissue model
Researchers found, using human respiratory epithelium organoids, that P. aeruginosa breaches respiratory epithelia by goblet cell invasion.
-
ArticleRecce Pharmaceuticals’ synthetic approach to combatting AMR
As antimicrobial resistance continues to advance, novel therapeutics are needed that stop infection and do not contribute to resistance. Australian biotech Recce Pharmaceuticals is paving the way for a new class of synthetic anti-infectives and providing hope for those with resistant infections. Recce’s lead candidate, RECCE® 327 (R327), is a ...
-
News
Uncovering the functional role of sRNAs in bacterial adaptation
Researchers find how antibiotic treatments influence the microbiota, providing new strategies for preventing antibiotic-induced damage.
-
NewsNew AI model could help to overcome antibiotic resistance
Six molecules that had potent antibacterial effect against one of the world’s most dangerous antibiotic-resistant bacteria were generated.
-
NewsNew antibiotic overcomes antimicrobial mechanisms
Researchers have created a novel molecule, which has an improved ability to bind to bacterial ribosomes, with a completely synthetic system.
-
NewsIncreased persister cells production leads to antibiotic resistance
Using clinical E. coli bacteraemia isolates, researchers found that high-persister mutants evolved which contributed to antibiotic failure.
-
NewsDisrupting the mechanism pathogens use to infect host cells
New understanding of the communication system between pathogens and host cells provides a way to avoid antimicrobial resistance.
-
ArticleAntimicrobial resistance with Recce Pharmaceuticals
In this exclusive interview, Drug Target Review's Taylor Mixides interviews James Graham, CEO of Recce Pharmaceuticals, they explore the company's approach to combat the growing global threat of antimicrobial resistance (AMR). Recce Pharmaceuticals is at the forefront of developing a new class of synthetic anti-infectives with a unique mechanism of ...
-
News
Genetic scar left in the genome of bacteria
New study reveals how pneumonia cells become resistant to penicillin through evolutionary gateway.
-
ArticleUnleashing the power of AI in target discovery and resilience against disease
In this interview Drug Target Review’s Izzy Wood and Olivia Cavlan, Chief Corporate Development and Strategy Officer at Alchemab Therapeutics Ltd, uncover the untapped potential of AI in target discovery. Alchemab’s revolutionary platform aims to identify common antibodies in resilient individuals and uncover the antigens that contribute to their disease-fighting ...
-
NewsDrug helps reduce bacterial antibiotic resistance
US researchers uncover a new drug that reduces the ability of bacteria to develop antibiotic resistance, prolonging the antibiotic effectiveness.
-
NewsGut bacterial interactions limit antibiotic efficacy on C. difficile
A recent study from the University of Wisconsin-Madison suggests that interactions between gut bacteria can influence the effectiveness of antibiotics against C. difficile infections.
-
NewsAntibiotic-resistant bacteria contaminates hospitals’ ICU in China
The drug resistant bacteria: CRAB, came into the ICU in hospitals in Hangzhou, China, creating an urgent need for a thorough understanding of the persistence, transmission, and evolution of CRAB populations in such environments.
- Previous Page
- Page1
- Page2
- Page3
- Next Page